Member Info for Ella10

Hi Westlad,
At this stage I don't think there is anything concrete with the licences. I think the mining licence over the main resource area has been sitting waiting for transfer for quit a long time, it looks like Galileo have an application in for exploration over some of the other area. The LEL covering a much wider area is just an application at the moment. A lot of folk do seem to 'chance their arm' applying for areas they don't have the rights - if this is the case it may get thrown out. The legacy issues around Ka****u will also presumably have some impact on what happens to it. I think it's just a case of wait and watch at the moment. If you are concerned it may be worth dropping the company an email.

Hi DC,
I really can't hazard a guess at what is going on. The application covers what I believe is both the exploration and mining licences (resource area). Itmay still be getting set up properly so a temporary state, Perhaps it is someone changing their arm and the application will be thrown out or perhaps ????

I see there is some activity in the mining cadastre in the Ka****u licence area - no idea what to make of it.

Hi OC,
I just found it interesting. The diagram in the announcement is interesting. This is a really exceptional result so a comparison with XTR results isn't fair. Hole 38? I think 35 was exceptional and would be quite happy with a few more like it but I wouldn't complain if the XTR SP increases 4 fold.

I found this interesting from Filo Mining

https://filo-mining.com/news/filo-mining-reports-1-224m-at-1-26-cueq-extends-122591/

Good morning Fulmar,
I hope you have a good story ready for next week - I'm looking forward to hearing it. :-)

CB mentiined the feeder zone in the interview. Suddenly they are very interested in the area between Ascot and Racecourse with an additional survey mentioned. I assume that if we find the feeder zone we are likely to also find some higher grade mineralisation? It wasn't immediately obvious to me what was driving the interest in that area although there was mention of higher grade molybdenum in the assays.

He uses the term 'decision to mine' in the AFP RNS so worth a look from that perspective.

More great publicity for CB - you guys are doing a great job! Keep it up ;-).

Prior to today I got the impression that they accepted there was a gap between Racecourse and Ascot but that definitely seems to have changed. CB mentioned various pointers to the fact that Ascot is closer to the feeder zone. Their keeness to drill between Ascot and Racecourse suggests to me that they could think the feeder zone is in that location. If it is what is it likely to give us apart from, presumably, more info about the system?

Cygnus,
I think part of that decision would be the plans for the other tenements and how prospective they think they are. I realise very little has been done on them. ProspectOre completed their acquisition while Xtract was in the process of acquiring Prospectore so it seems likely they have some plan in mind.

Good to see that little bit of extra gold :-). It is interesting that the higher grade area on hole 35 seems to go across the intrusion rather that to either side.
http://www.rns-pdf.londonstockexchange.com/rns/9971Y_2-2022-1-19.pdf
I assume the Ascot assays were prioritised as everyone likes good news but also in order to help guide further drilling.

https://www.yourgene-health.com/about/the-y-series/your-comment/87-the-y-series/your-comment/1889-new-year-new-regulations-19-january-2022

Thanks RegulatorUK,
The CDTA requirements are embodied in (not in addition to ) the modified MDR 2002 requirements (regulation 38 and 39).
But the gov website states that you have a choice until June 2023
'In Great Britain (England, Wales and Scotland), devices must conform to the UK MDR 2002, the EU MDR (until 30 June 2023), or the EU IVDR (until 30 June 2023) in order to be registered with the MHRA.'
I realise that there was also a statement that all covid test need to comply with CDTA but I don't see how this aligns with the above statement.
https://www.legislation.gov.uk/uksi/2021/910/contents/made

Hi Bakky,
Yeah I would like to understand the regulations and the way they are called out. Too long spent working in a different highly regulated industry...

https://www.legislation.gov.uk/uksi/2021/910/contents/made

Hi Bakky,
MDR 2002 has been modified so that regulation 38 calls on the requirement for CDTA. MDR 2002 regulation 39 gibmves the process for exemption and this is quoted in the protocol doc.
The mods to MDR 2002 to cover CDTA are in the link below. I therefore don't think the requirement can override the allowance for EU approved devices (but am not certain how the EU exemptions until 2023 are called out).
https://www.legislation.gov.uk/uksi/2021/910/contents/made

Hi RegulatorUK,
I am trying to understand how yhe regulation flows down. My understanding in that the CDTA requirement are in effect 38 of MDR 2002 and not part of the EU MDR.
The following is off the ukgov website
'All medical devices, including IVDs, custom-made devices and systems or procedure packs must be registered with the MHRA before being placed on the Great Britain market. In Great Britain (England, Wales and Scotland), devices must conform to the UK MDR 2002, the EU MDR (until 30 June 2023), or the EU IVDR (until 30 June 2023) in order to be registered with the MHRA. In addition, devices that have been CE marked under the EU MDD, EU AIMDD or EU IVDD will continue to be accepted on the Great Britain market until 30 June 2023 if their certificates remain valid for the EU market under the transitional arrangements in the EU MDR and EU IVDR.'

How does the CDTA requirement feed into the eu requirements?(or is there something else that calls this out).

I am no expert here but my understanding is that the CDTA process is part of MDR 2002. Did Visitect not have EU CE approval that would still allow it to be sold in the UK?

'All medical devices, including IVDs, custom-made devices and systems or procedure packs must be registered with the MHRA before being placed on the Great Britain market. In Great Britain (England, Wales and Scotland), devices must conform to the UK MDR 2002, the EU MDR (until 30 June 2023), or the EU IVDR (until 30 June 2023) in order to be registered with the MHRA. In addition, devices that have been CE marked under the EU MDD, EU AIMDD or EU IVDD will continue to be accepted on the Great Britain market until 30 June 2023 if their certificates remain valid for the EU market under the transitional arrangements in the EU MDR and EU IVDR'

Davand,
I agree it's confusing but I can see why Yourgene don't want to start explaining regulations to individual shareholders. It is likely to end up in confusion at some later date. Provided they are not withholding market sensitive information or selling tests illegally then I can understand why they don't want to engage in explanations here.
'On 31 July 2020, Elucigene Diagnostics, part of the Yourgene Health group, made a manufacturer's Declaration of Conformity that their Clarigene™ SARS CoV-2 test complies with the provisions of Directive 98/79/EC on In Vitro Diagnostic Medical Devices and that the in vitro diagnostic medical device can now be CE marked and placed on the European market'

My understanding is that the CDTA process is part of MDR 2002. Il